• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    BioTime, Inc. Announces Pricing of Public Offering of Common Stock

    Investing News Network
    Jun. 16, 2016 08:05AM PST
    Biotech Investing

    ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine, today announced the pricing of an underwritten public offering of 7,322,176 shares of its common stock at a public offering price of $2.39 per share. The gross proceeds to BioTime, Inc. …

    ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company
    focused on developing and commercializing novel therapies in the field
    of regenerative medicine, today announced the pricing of an underwritten
    public offering of 7,322,176 shares of its common stock at a public
    offering price of $2.39 per share. The gross proceeds to BioTime, Inc.
    from this offering are expected to be approximately $17.5 million,
    before deducting underwriting discounts and commissions and other
    estimated offering expenses payable by BioTime, Inc. The offering is
    expected to close on or about June 21, 2016, subject to customary
    closing conditions. BioTime, Inc. has also granted to the underwriters a
    30-day option to purchase from it up to an additional 1,098,326 shares
    of its common stock.
    BioTime, Inc. intends to use the net proceeds from this offering to fund
    its research and development activities and for working capital and
    other general corporate purposes.
    Oppenheimer & Co. Inc. is acting as sole book-running manager for the
    offering. Chardan is acting as the co-manager for the offering.
    Ladenburg Thalmann & Co. Inc. is acting as a financial advisor for the
    offering.
    A registration statement relating to these securities was previously
    filed with and has become effective by rule of the Securities and
    Exchange Commission (SEC). A preliminary prospectus supplement and the
    related prospectus have been filed with the SEC and are available on the
    SEC’s website at www.sec.gov.
    A final prospectus supplement and the related prospectus will be filed
    with the SEC and available on the SEC’s website at www.sec.gov.
    Copies of the prospectus supplement and accompanying prospectus relating
    to the offering may be obtained, when available, from Oppenheimer & Co.
    Inc., 85 Broad Street, 26th Floor, New York, New York, 10004, Attn:
    Syndicate Prospectus Department, or by telephone at (212) 667-8563, or
    by e-mail to EquityProspectus@opco.com.
    This press release shall not constitute an offer to sell or the
    solicitation of an offer to buy, nor shall there be any sale of, the
    shares in any state or other jurisdiction in which such offer,
    solicitation or sale would be unlawful prior to the registration or
    qualification under the securities laws of any such state or other
    jurisdiction.
    About BioTime, Inc.
    BioTime, Inc. is a clinical-stage biotechnology company focused on
    developing and commercializing novel therapies in the field of
    regenerative medicine. The foundation of its core therapeutic technology
    platform is pluripotent cells that are capable of becoming any of the
    cell types in the human body. BioTime, Inc.’s research and other
    activities have resulted, over time, in the creation of other
    subsidiaries that address other non-therapeutic market opportunities
    such as cancer diagnostics, drug development and cell research products,
    and mobile health software applications.
    BioTime, Inc.’s common stock is traded on the NYSE MKT under the symbol
    BTX. For more information, please visit www.biotimeinc.com
    or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and
    Google+.
    Forward-Looking Statements
    Certain statements contained in this release are “forward-looking
    statements” within the meaning of the Private Securities Litigation
    Reform Act of 1995. Statements pertaining to future financial and/or
    operating results, future growth in research, technology, clinical
    development, and potential opportunities for BioTime, Inc. and its
    subsidiaries, along with other statements about the future expectations,
    beliefs, goals, plans, or prospects expressed by management constitute
    forward-looking statements. Any statements that are not historical fact
    (including, but not limited to statements that contain words such as
    “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”
    should also be considered to be forward-looking statements.
    Forward-looking statements involve risks and uncertainties, including,
    without limitation, risks inherent in the development and/or
    commercialization of potential products, uncertainty in the results of
    clinical trials or regulatory approvals, need and ability to obtain
    future capital, and maintenance of intellectual property rights. Actual
    results may differ materially from the results anticipated in these
    forward-looking statements and as such should be evaluated together with
    the many uncertainties that affect the business of BioTime, Inc. and its
    subsidiaries, particularly those mentioned in the cautionary statements
    found in more detail in the “Risk Factors” section of its Annual Reports
    filed with the SEC (copies of which may be obtained at www.sec.gov).
    Subsequent events and developments may cause these forward-looking
    statements to change. BioTime, Inc. specifically disclaims any
    obligation or intention to update or revise these forward-looking
    statements as a result of changed events or circumstances that occur
    after the date of this release, except as required by applicable law.
    To receive ongoing BioTime corporate communications, please click on the
    following link to join our email alert list: https://news.biotimeinc.com.

    clinical trialsladenburg thalmannregenerative medicinepublic offering
    The Conversation (0)

    Go Deeper

    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Row of test tubes and pipette with chemical droplet chemical coming from it.

    Top 5 Small-cap Biotech Stocks of 2025

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×